EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Five-Year Treatment Outcomes with 0.19 µg Fluocinolone Acetonide in Radiation-Induced Maculopathy

Lena Zimmermann, Luise Grajewski, Christiane Kneifel, Ilja F Ciernik, Lothar Krause

Ocular Oncology and Pathology · 26.05.2026 · 1-9

DOI: 10.1159/000552282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 26.05.2026. Verfasst von Lena Zimmermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic macular edema is a well-recognized complication of radiation-induced maculopathy (RM). Current treatment methods vary in efficacy and clinical benefit. The potential of fluocinolone acetonide (FAc) slow-release intravitreal implants (Iluvien® implant) remains unclear. We hypothesized that local continuous delivery of low-dose corticosteroids may improve RM symptoms.

Methods

This study included 8 patients who presented with RM after 106-Ru-plaque brachytherapy (n = 3), proton beam therapy (n = 2), or stereotactic radiation therapy (n = 3) with photons. All eyes were initially treated with triamcinolone injections but proved refractory to steroids. The Iluvien® implant was injected, and patients were followed to monitor clinical improvement.

Results

After 5 years, visual acuity improved in 3 patients, remained stable in 2 patients, and decreased in 2 patients. One patient progressed to no light perception following treatment. One patient was lost to follow-up after 5 years. Central macular thickness was reduced in 5 patients, stable in 1 patient, and increased in 1 patient.

Discussion

Slow-release FAc implants are a promising treatment option to improve the anatomical structure of the fovea and visual function. They may also reduce the frequency of intravitreal injections and the overall therapeutic burden.

Schlagwörter

Stichwörter der Autor:innen

Choroidal melanomaChronic macular edemaFluocinolone acetonideRadiation maculopathy

Autor:innen und Institutionen

  • Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
  • Department of Radiation Oncology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.

Zitieren

APA

Zimmermann, L., Grajewski, L., Kneifel, C., Ciernik, I. F., & Krause, L. (2026). Five-Year Treatment Outcomes with 0.19 µg Fluocinolone Acetonide in Radiation-Induced Maculopathy. Ocular Oncology and Pathology, 1-9. https://doi.org/10.1159/000552282

Vancouver

Zimmermann L, Grajewski L, Kneifel C, Ciernik IF, Krause L. Five-Year Treatment Outcomes with 0.19 µg Fluocinolone Acetonide in Radiation-Induced Maculopathy. Ocular Oncology and Pathology. 2026:1-9. doi:10.1159/000552282

BibTeX
@article{Zimmermann2026,
  author = {Zimmermann, Lena and Grajewski, Luise and Kneifel, Christiane and Ciernik, Ilja F and Krause, Lothar},
  title = {Five-Year Treatment Outcomes with 0.19 µg Fluocinolone Acetonide in Radiation-Induced Maculopathy},
  journal = {Ocular Oncology and Pathology},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000552282}
}
Kostenlos starten →